The firm will share new overall survival data from the INAVO120 trial with regulators to support the breast cancer drug's approval.

The antibody-drug conjugate improved progression-free survival for patients previously treated with hormone therapy.

DelveInsight’s, “Metastatic Breast Cancer Pipeline Insight” report provides comprehensive insights about 100+ companies and ...